Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen by unknown
molecules
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pond to foreign protein antigens only after they are processed in
the surface of an AM in association with the appropriate MHC
they only see processed fragments, T cells are generally unable
n native and denatured proteins (2). It is also possible to re-
place protein antigens with synthetic peptides that contain the complete antigenic
determinant recognized by T cells (3-6). In effect, antigen processing reduces pro-
tein antigens to a lowest common denominator recognizable by T cells (7, 8).
distinct pathways for antigen processing have been described. The
e for the protease binding sites,
enzymes process exogenous antigens
by
the
AM (L 9-13, 15). Presumably, this would be a major pathway by which vac-
cine antigens could elicit T cell immunity- Recently, a second process
has been recognized, by which nonendosomal proteases produce a different set of
antigenic fragments for antigen presentation (5, 15-17). Up to now, this pathway
was thought to be accessible only to endogenous viral antigens produced by infected
cells. However, if these two pathways are mutually exclusive, it would be difficult
for exogenous vaccine antigens to elicit protective T cell immunity against infected
cells expressing viral antigens endogenously.
In this paper we demonstrate that cloned human T cell lines, each specific for
a single determinant on the surface antigen ofhepatitis B virus (HBsAg), can re-
spond to exogenous as well as endogenous antigen. Exogenous antigen was used
in the immunization and during the growth and selection of the T cell clones in
itro. Nevertheless, each T cell line responded equally well to infected cellsexpressing
exogenous antigen presented by the same AMs. In ad-
igen processing requirements W each T cell
genous and exogenous antigen. Different T cell
endosomal or nonendosomal processing: for our T
led 0 each processing pathway could not substi-
, hepatitis B surface antigen; HBV, hepati
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tute for the peptide products of the otherpathway . Either processing pathway could
handle the antigen, regardless ofwhether it came from an exogenous orendogenous
source. These results reveal an underlying symmetry between exogenous and en-
dogenous antigen, which may help explain howT cells elicited by a noninfectious
component vaccine can play an active role in the immune response to a subsequent
infection with live virus.
Materials and Methods
Antigens .
￿
HBsAgwas purified from the plasma ofa chronic carrier by Sepharose 6B chro-
matography followed by affinity chromatography as described previously (18) . It is known
to contain ti5% pre-S antigens, including pre S, and pre-S2 . Purified recombinant yeast-de-
rived hepatitis antigens were the gift ofDr. Ronald Ellis (Merck, Sharp andDohme Research
Laboratories, West Point, PA) and included : S antigen, Pre- " S,, Pre-S2, and long S (pre-S,
+ pre-S2 + S) (19) . Synthetic peptides 21-47 ofthe pre-S, region and 120-145 ofthe pre-S2
region were produced on an Applied Biosystems solid phase peptide synthesizer and were
a gift ofDrs . Frank Robey andMei YingYu (Office ofBiologics Research and Review, FDA) .
Pre-S, peptide 1-28 was a gift ofDr. John Gerin (Georgetown University, Washington, DC) .
Pre-S, peptide 12-32 was a gift of Dr . Brad Jameson (California Inst . of Technology,
Pasadena, CA), as were the other pre-S, peptides.
Monoclonal Antibodies.
￿
Monoclonal anti-HLA-ABC was purchased from Cappel Labora-
tories (Malvern, PA) and was added to culture at 5 ug/ml . Monoclonal anti-HLA-DR clone
L243 was purchased from Becton Dickinson & Co. (Mountain View, CA). It was used to
pretreat APC overnight at a concentration of 2 wg/ml as described previously (20).
Recombinant Vaccinia Viruses .
￿
Vacciniarecombinants expressing HBsAg were a gift of Drs .
Bernard Moss, Geoffrey Smith, and Kuo-ChiChen (National Institute ofAllergy and Infec-
tious Diseases, Bethesda, MD) . Recombinant v55 expresses the S region only, and the pro-
tein product is secreted as 22-nm particles (21) . Recombinant v73 expresses the entire pre-
S +S region, and the protein product remains cell associated until the cell dies (22, 23) . The
vaccinia recombinants were lightly UV treated (20 s at 14 cm from a 700-W lamp with a
peak wavelength of 254 nm) so they would express early genes (including the hepatitis an-
tigens) without releasing infectious vaccinia virus . Higher doses ofUV light gave decreased
expression ofS antigen, as measured by RIA and a proportionate decrease in T cell stimula-
tion (data not shown) . Before infection, the EBV cells were treated with mitomycin c (50
wg/ml) for 40 min, washed three times, and then exposed to the vaccinia recombinant for
1 h at a multiplicity of infection of 10 . They were then washed to remove excess free virus .
Subjects.
￿
Two individuals lacking antibodies to hepatitis B surface and core antigens re-
ceived three doses of plasma-derived (donor LL) or recombinant (donor SR) vaccine be-
tween 1 and 2 yr before these studies. Donors ofAPCs were HLA typed at the NIH Clinical
Center HLA laboratory.
Proliferation Assay.
￿
The T cell proliferation assay was performed as described previously
(24) . PBL were separated from heparinized blood by sedimentation onto a layer of Ficoll-
Hypaque . These cells were then depleted of adherent cells by incubating on plastic for 3 h
at 37OC . The nonadherent cells were added to culture at 4 x 105 per microwell with an ad-
ditional 10 5 irradiatedPBL (3,300 rad) as a source ofAPCs . Plasma-derived HBsAg or other
antigens were added at 2-4 ug/ml . After 4 d in culture, 1 WCi of [3H]thymidine was added
for an additional 18 h and labeled cells were harvested on an automated device. Incorporation
of [3H]thymidine into new DNA was measured in a liquid scintillation counter. Results are
expressed as the geometric means oftriplicate wells minus the medium control (A cpm). The
medium control value is given in parentheses, and the SEM was generally within 10% and
is not shown.
Establishing a T Cell Line and Cloning by LimitingDilution.
￿
The derivation and initial char-
acterization of the cloned LLl line from donor LL was described previously (25) . PBL from
donorSR were found to give a good proliferative response to HBsAg, so 10 microwells were
started in culture as described for the proliferation assay, except that the cells were harvestedJIN ET AL.
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on day7 andclonedby limiting dilution at 1 or 0.3 cellsper well . Cloning conditionsincluded
2 x 104 irradiated PBL feeder cells in round-bottomed wells, containing 50% RPMI 1640
and 50°Jo EHAA mediasupplemented with 100U/ml penicillin and 100 ttg/ml streptomycin,
2mM glutamine, 5 x 10-5M mercaptoethanol, 10% autologous serum, and 10% IL-2 (Cel-
lular Products, Buffalo, NY) . After 2-3 wk, proliferating cells were apparent in 67 of 480
wells . This cloning efficiency is typical of our results with human T cell clones . Of these,
24 were antigen specific, including 3 from the plates receiving 0.3 cells per well . The cloned
lines were propagated by repeated cycles of stimulation in microwells followed by expansion
in macrowells in the presence of 10% IL-2 . Two of the SR clones (SR45 and SR54) were
used in the present studies, because their HLA restriction and antigen processing require-
ments were found to contrast with those of LLl .
Results
Human T CellLinesSpeckforHBsAg
￿
Vaccinationwith plasma-derived or recom-
binant HBsAg elicits a detectable T cell response in a small proportion of people
tested (26) . As reported previously (25), we tested 20 vaccinees and found3 individ-
uals whoseTcells gaveasignificant in vitro proliferative response to exogenous HBsAg .
For each responder, the population of antigen-specificT cells was expanded by an-
tigen stimulation, and then cloned by the limiting dilution method . We obtained
aT cell line LLI from one donor andT cell clones SR45 and SR54 from a second
donor . Each of these clones wascharacterized forHLArestriction, epitope specificity,
ability to recognize endogenous antigen, and antigen processing requirements for
both endogenous and exogenous antigen .
HLA Restriction.
￿
T cell line LLI responds to HBsAg only when the HLA an-
tigens of theAPC match theHLA of the donor. We have determined which MHC
antigen wasrecognized as arestriction element by LLI by studyingPBL from family
membersJLandJoL forthe ability to presentantigen to the line . Asshown in Table
1, Exp . 1, PBL fromJL gave maximal antigen-specific stimulation, while PBL from
JoLandtheunrelated III gavenone at all. ComparingtheHLAtypesof each donor,
we observed that HLA-A1, B35, and C4 were presenton stimulatory and nonstimula-
tory presenting cells alike . HLA-All waspresent only on stimulatoryPBLand could
explain the observed pattern of stimulation . In other experiments, PBL from four
of five unrelated HLA-All donors gave maximal stimulation by HBsAg (Table I,
Exp . 2, shows three of these) . Thus, the LLI line recognizes HBsAg in association
with HLA-All .
In contrast, thetwo clones SR45 and SR54 appeared to recognize HBsAg in as-
sociation with HLA-DR7 . The donorSR typed asHLADR6,7, and theclones re-
spond to APCs bearing HLA-DR7 but notDR6 (as in Table IV and Fig . 2 below) .
mAbs to MHC class I or class II antigens were then tested for the ability to block
the antigen-specific response of each clone (Table II). mAbs to HLA-A,B,C com-
pletely inhibited the LLI response to plasma-derived HBsAg, while anti-HLA-DR
had little effect . Conversely, the monoclonal anti-HLA-DR inhibited the SR45 re-
sponse to yeast-derived HBsAg, while anti-HLAABC inhibited poorly. Interestingly,
anti-HLA-DR also completely inhibited the response ofSR54 to endogenously ex-
pressed HBsAg (discussed further below), while anti-HLA-ABC was less effective.
Thus, LLI responds to HBsAg in association with the MHC class I determinant
HLA-All, while SR45 and SR54 are specific forMHC class 11 .
Epitope Mapping!
￿
As shown in Table III A, yeast recombinant polypeptides de-296
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TABLE I
MHC Restriction of the LLI T Cell Line
TABLE II
MHC Class Ior II Restriction of T Cell Lines
MHC restriction ofthe LLI T cell line on family members' PBL in Exp. 1 or on PBL from unrelated donors
in Exp. 2 . JL antigen-presenting cells, which stimulate the clone in the presence of HBsAg, share fourHLA
class I antigens with the propositus LL . However, of these only HLA-A11 is lacking in the JoL cells that
do not stimulate, suggesting that HLA-Al l is the class I restriction element,
rived from different regions ofHBsAg were tested for the ability to stimulate each
T cell line . LL1 was stimulated by long S (containing pre-Si + pre-S2 + S) and
by pre-S1 alone, but not by S antigen . Conversely, SR54 was stimulated by long
S and by S antigen alone, but not by pre-Si . SR45 was also stimulated by recom-
binant S antigenalone which ishow it was derived. Thus, LLI recognizes an epitope
in the pre-Si region, while SR54 and SR45 respond to epitopes in the S region of
HBsAg .
Further precision in mapping the pre-SI epitope recognized by LLI required the
The same treated or untreated EBV-derived B cells (from donor LL) were used
as the APC for all three T cell clones . For clone SR54, theEBV line was in-
fected with vaccinia recombinant v73 as described in Materials and Methods .
The APC were either pretreated overnight with monocloanl anti-HLA-DR
(2 jig/ml), or cultured in the presence of anti-HLA-ABC (5 uglml). Data are
expressed as A cpm, with the medium controls in parentheses .
* LL-EBV as APC with exogenous HBsAg (2 pg/ml) .
x v73-infected LL-EBV expressing endogenous HBsAg.
Exp. APC donor Cells A
HLA
B C DR
[ 3H)TdR
incorporation
No Ag + HBsAg
d cpm
1 LL PBL 1/11 8/35 4 7 1,227 145,086
JL PBL 1/11 35/35 4 4 1,508 134,719
Family members EBV 1,709 61,497
JoL PBL 1/1 8/35 4 7 447 899
EBV 606 668
IB PBL 2,3 18,35 4,6 ND 330 2,642
2 LL PBL 1,11 8,35 4 7 (1,303) 19,610
BL PBL 11,23 14,17 5 6,8 -558 15,635
Unrelated donors TS PBL 11,33 14,62 4 1,8 -10 24,376
DB PBL 11,31 51,35 4 ND 808 12,674
WF PBL 1 8 6 3 460 314
IB PBL 2,3 18,35 4,6 ND 339 131
mAb LLI*
T cell line
SR45* SR541
None 61,133 101,269 73,435
Anti-ABC -486 64,721 22,185
Anti-DR 47,975 15,793 990
Medium control (799) (1,588) (837)JIN ET AL.
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TABLE III
Fine Specificity of Human T Cell Linesfor HBsAg
Each T cell line was stimulated with exogenous or endogenous HBsAg polypeptides from
the pre-S or Sregion . InA, each exogenous antigenwasadded at 2 pg/ml with HLA-matched
EBV-derivedB cells as the APC. In B, the same B cells were infected with v55 (expressing
S antigen) or v73 (expressing pre-S + S antigen), at a multiplicity of infection of 10, in-
cubated for 1 h at 37°, washed, and added to culture as infected stimulator cells expressing
endogenous HB&Ag.
' For the LL1 T cell line, the haploidentical JL-EBV B cell line was used.
1 For the SR54 T cell line, the DR-matched 898-EBV B cell line was used.
use of synthetic peptides . Recent work with cloned T cell lines specific for avariety
of antigens has shown that complete epitopes recognized by T cells may be con-
tained on synthetic peptides corresponding to the antigenic determinant on the pro-
tein (reviewed in references8 and 27) . Thus, we tested an overlapping series of syn-
thetic peptides corresponding to thepre-Si sequence for the ability to stimulate LL1.
As shown in Fig . 1, the response to recombinant yeast-derived pre-Si was equal to
the response to the entire pre-Si + pre-S2 + S antigen . In addition, three of the
synthetic pre-St peptides gave maximal stimulation, indicating that the entire an-
tigenic determinant recognized by LL1 is contained on these peptides. The three
peptides 1-28, 12-32, and 21-47 overlap at residues 21-28 . We conclude that the
epitope recognized by LLl is located in this region and has the sequence Pro-Leu-
Gly-Phe-Phe-Pro-Asp-His (28) .
Recognition ofEndogenous HBsAg .
￿
An important question for vaccine-immuneT
cells is whether they can respond to infected cells that express viral antigens en-
dogenously . To get endogenous expression of HBsAg in lymphocytes, we infected
the cells with vaccinia recombinants that were constructed with either the S region
only (v55) or with the entire long S region (v73), including pre-Si + pre-S2 + S.
Previous studies have shown that cells infected with v55 produce S antigen and se-
crete 22-nm particles, while cells infected with v73 produce long S protein but the
antigen remains a monomer and is not secreted (22). As shown in Table IIIB and
Fig. 2, LLl responds to v73-infected cells that express pre-S1 + pre-S2 + S, but
not to v55-infected cells that express S antigen only . SR54 responds well to stimu-
lator cells infected by either recombinant virus, while neitherT cell line responds
A. Exogenous recombinant antigen
APC Antigen
13H]TdR incorporation
LLl SR54
d cpm
B cell line PreSj +PreS2+S 26,450' 13,8651
B cell line PreSj 37,460 600
B cell line S 2,587 68,457
B cell line Medium control (2,176) (1,588)
B. Endogenously expressed antigen
Stimulator cell Antigen
infected by expressed
v73 PreSI +PreS2+S 44,803' 76,1061
v55 S -865 47,008
Vaccinia wild type - -1,383 1,112
Uninfected control - 1,911 2,094NSE TO HBsAg
Pro-Leu-Gly-Phs-Phe-Pro-Asp-His
FiGuRE 1 .
￿
T cell response to synthetic
peptides ofHBsAg. Epitopemapping with
synthetic peptides .LLlwas incubated with
each peptide or with recombinant pre-S1
antigen at a concentration of 0.1 pM, or
with recombinant pre-S2 antigen at 0.3
pM . The identical pattern was obtained
with each peptide at 0.5 pM . Three over-
lapping peptides gave maximal stimula-
tion . They shareamino acids 21-28, and
the shared sequence is shown .
to cells infected by vaccinia wild type . SR45 also responds to v55, but only when
the infected stimulator cell matchesat HLA-DR7(Fig. 2 C) . The response to endog-
enous antigen was generally greater than or equal to the response to exogenous an-
tigen forthe doses tested . For all three clones, the response to v55-infected cells cor-
related with whether the clone responded to exogenous S antigen (Table III) . The
results are compatible with each clone recognizingthe same epitope forendogenous
as well as exogenous antigen .
Thedemonstration that theTcells areresponding to endogenous antigendepends
on the assumptions that (a) exogenous HBsAg does notcontaminatethe recombinant
virus and (b) HBsAg is not secreted by an infected cell and taken up and processed
as exogenous antigen by a second cell . This was supported by four linesofevidence :
FIGURE 2 .
￿
T cell response to infected stimulator cells . Each T cell line was incubated in the
presence ofincreasing numbers ofHLA-matchedEBVderivedB cells that were either uninfected,
or infected with vaccinia wild type (noHBsAg), v55 (expressing S antigen), or03 (expressing
pre-S + S antigen) . With uninfected APCs, the response to exogenous antigen is shown as a
closed circle, andthe background forLLl was 141 cpm, 1,522 cpm forSR54, and 802 cpm for
SR45 (which increased to 92,080 cpm in the presence of HBsAg).
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CELL RESP
Incorporstion IAcPrn)
Exp . 1 Ex¢il
t 120
Pre S, F-- -+ 31,621 54,321
Pre S2
121 174
-1401 NO
1-21 4937 NO
1-28 ~--~ 28.868 e6,432
12-32 23,601 NO
21-47 r-i 25.475 38 .821
32-53 r--1 1567 NO
53-73 H -191 NO
94-117 H 1801 1715
120-145 r-i 1336 NO
Pre S+S Antigen NO 82,944
S Antigen NO 174
Medium Control 5374 1,731JIN ET AL.
TABLE IV
Mixing Experiment
Mixing experiment to detect secretion andreuptake ofendogenously expressed
HBsAg. Infected 1101 B cells of the irrelevant HLA type (DR-6) were tested
alone or in the presence ofuninfectedJL Bcells of the relevant HLAtype (DR-7)
for the ability to stimulate SR54. If the v73-infected cells secreted HBsAg, then
it could be taken up and presented by the uninfected JL B cells.
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First, there was little or no detectable exogenous HBsAg associated with the pure
virus, as measured by RIA (datanot shown). Second, HBsAg production was under
the control of viral genes: excessive UV irradiation of v55 (3-30-fold greater than
the optimal dose) gave an exponential decrease in antigen production and an equal
decrease in T cell stimulation (data not shown). Third, v73 is known to express en-
dogenous pre-St + pre-S2 + S, but this long S antigen is not secreted into the cul-
ture medium, as shown by Western blots (22). Fourth, we tested whether the T cell
response to v73-infected cells could be due to reuptake of secreted antigen (Table
IV). We mixed infected 1101 cells of the mismatched HLA type (DR6) with unin-
fected JL cells of the matched HLA type (DR7). The JL cells were competent
presenters ofexogenous antigen as shown in the last line, and ofendogenous antigen
as shown in the first line ofthe table. However, when mixed with infected 1101 cells
they were unable to take up enough antigen to stimulate clone SR54. Thus, T cells
recognize the endogenous antigen of infected cells directly, without resorting to a
second APC.
Distinct Antigen ProcessingPathways. Previous studies have shownthat T cellscom-
monly recognize the same antigenic determinant whether contained on a native protein
or a synthetic peptide (8, 27). Synthetic peptides can also substitute for endogenously
expressed viral antigens (5, 16, 17). In both cases, the peptides are fully competent
to stimulate a response, suggesting that partial proteolytic degradation is important
for the presentation of native protein antigens from an endogenous or exogenous
source. In addition, the steps of antigen processing have been divided into two dis-
tinct pathways based on sensitivity to inhibitors of endosomal proteases. The en-
dosomal pathway has frequently been implicated in the processing ofexogenous na-
tive proteins for MHC class II-associated antigen presentation. It is readily inhibited
by chloroquine or leupeptin (9-13). The nonendosomal pathway is thought to pro-
cess endogenously expressed viral proteins primarily, since CTL recognize infected
target cells despite pretreatment with chloroquine, and also recognize uninfected
targets when pulsed with synthetic peptides corresponding to viral antigens but not
with the native protein antigens (5, 17). Thus, an alternative, nonendosomal pro-
Infected cell Uninfected cell
DR of
infected cell
Proliferation
of SR54
d cpm
JL-EBV - DR7 20,876
1101-EBV - DR6 637
JL-EBV 1101-EBV DR7 11,143
1101-EBV JL-EBV DR6 -1,790
JL-EBV - (2,275)
1101-EBV - -835
JL-EBV + HBsAg - 33,344300
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TABLE V
Antigen Processing Requirements for Exogenous and Endogenous HBsAg
For LLl, the autologous EBV-derived B cell line was used either as APCS or
as v73-infected stimulator cells in the presence or absence of 1 mM leupeptin.
The background response with uninfected B cells was 141 cpmand with the vac-
cinia infected control cells was 17 cpm above background. For SR54, an HLA-
DR7-matched B cell line (898) wasused in the same way, giving abackground
of 1,522 cpmwith uninfected cells andavacciniacontrol of21 cpmbelow back-
ground. SR54 requires endosomal processing (leupeptin-sensitive) of both
endogenous and exogenous HBsAg, while LLl does not require the leupep-
tin-sensitive processing step for either source of antigen.
cessing pathway was postulatedto work primarily on endogenous viral antigens, while
the endosomal processing pathway was thought to handle exogenous antigens (5,
15, 17).
Since our T cell lines recognize both endogenous and exogenous HBsAg, we could
test whether there is a strict segregation of processing pathways, or whether each
processing pathway is accessible to both internal and external antigen. An example
of such an experiment is shown in Table V The class I-restricted LL1 response to
exogenous HBsAg is totally resistant to leupeptin inhibition, and so is the response
to endogenous HBsAg produced by v73 infection. This suggests that the nonen-
dosomal processing pathway is readily accessible to both exogenous and endogenous
antigen. In contrast, the class II-restricted SR54 response to HBsAg is totally in-
hibited by leupeptin, regardlessofwhether the antigen comes from outside or inside
the cell. Thus, the endosomal pathway is also accessible to both forms of antigen.
The complete shutdown of the lysosomal pathway indicated by the inhibition ofthe
TABLE VI
Chloroquine Effect on the Response to Endogenous HBsAg
Chloroquine inhibits the SR54 response but notthe LL1 response to endogenous
HBsAg. EBV-derived Bcells from a single donor whowashistocompatible to
both LL and SR were infected with v73 for 1 h, followed by 1-h treatment with
nothing or 0.1 mM diloroquine. They were washed andadded to culture as stimu-
latorcells. V73-infected cells stimulated LLldespite chloroquine treatment, while
the SR54 response to the same cells was 94°% inhibited. TheLLl background
with uninfected Bcells was 3,212 cpm, and the SR54 background was1,451 cpm.
T cell done Stimulus
[3H]TdR
Alone +
Incorporation
Leupeptin (1 mM)
LL1 Exogenous HBsAg 25,932 43,339
v73 infection 34,829 64,446
SR54 Exogenous HBsAg 71,042 1,486
v73 infection 23,134 1,902
Stimulator cell [3H]Thymidine incorporation
T cell line infected by Alone + Chloroquine (100 gM)
Acpm
LLl v73 122,042 96,051
SR54 v73 88,766 4,990JIN ET AL.
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SR54 response has no effect on the response of LL1, other than to increase it by
65 % or more. Thus, the twoprocessing pathways areindependent, andtheproducts
of one pathway cannot substitute for the other in stimulation of T cells.
As shown in Table VI, we repeated this experiment with chloroquineas the inhib-
itor of endosomal proteases. However, we could only test the effect of chloroquine
on endogenous antigen, since we were unable to pulse the APCs with exogenous
antigen. Once again, full inhibition of the endosomal pathwaywas indicatedby the
94% inhibition of SR54, but LLI continued to respond to the antigen maximally.
Thus, endogenous antigencan stimulate SR54 via achloroquine sensitive pathway,
or it can stimulate LL1 via a chloroquine insensitive pathway. The results in these
two tables suggest that two distinct pathways exist for processing antigens that will
eventually stimulate T cells like LLI or SR54. Each T cell sees the product of one
pathwayonly. Butboth pathways are accessible to endogenous and exogenousantigens.
Discussion
We have found that plasma- or yeast-derivedhepatitis B vaccine can elicit human
T cells immune to the preS or S regions of HBsAg. They recognize HBsAg in the
contextof MHC classIin some cases or class II antigens in othercases. Each cloned
T cell line responds to endogenously expressedviral antigen as well as to exogenous
antigen. Although each of the T cell lines recognizes processed antigen, more than
oneproteolytic pathwayis available to processviral proteins into antigenic fragments
that can be recognized by the T cell lines.
The antigenic determinant recognized by LLI mapped to the pre-Si region,
based on the response to recombinant pre-Si and long S and the failure to respond
to S alone. More precise epitope mapping was based on synthetic pre-Si peptides
1-28 and 21-47, which stimulate the line (as does 12-32), while other pre-Si pep-
tides do not. The antigenic determinant consists of amino acids 21-28, which has
the sequence Pro-Leu-Gly-Phe-Phe-Pro-Asp-His (28). Presumably, this'peptide con-
tains distinct functional sites for MHC association (with HLA-A11) and forbinding
by the antigen receptor of LLI (29-32). This site is close to but distinct from the
pre-Si site 12-21 identified by Milich et al. (33) as the pre-Si antigenic determinant
recognized by mouseTcells in association with MHC class II antigens. They found
that T cells specific for this site could provide T helper function to B cells specific
for the S region (33). The LLI T cell line is different in that it responds to peptide
21-28 in association with MHC classI antigens, andwe do not as yet know whether
it provides helper function.
The sequence of 21-28 fits well into theparadigm ofGly-hydrophobic-hydrophobic-
Pro-charged amino acid proposed by Rothbard et al. (27, 34). The closest reported
analogue is peptide 111-120 of influenza hemagglutinin, which is presented in as-
sociation with class II antigens in the mouse (35). It is not clear whether peptides
that associate with MHC class I antigens will follow the same or adifferent pattern
from those that associate with class II antigens (7, 8). However, in both cases, we
presume that antigen processing is required because peptides can bind to MHC
molecules but native proteins cannot (13, 30-32). LLI responds well to synthetic
peptides, and we presume that the independence of endosomal processing reflects
use of a nonendosomal processing pathway, rather than the absence of processing.
Nonendosomal processing pathways are found in alarge variety of cells (36). Or-302
￿
HUMAN T CELL RESPONSE TO HBsAg
Exogenous Protein or Peptide
FIGURE 3.
￿
Schematicofantigen
processing. Endosomal process-
ing (in the circle) and nonen-
dosotnal processing pathways
are accessible to both exogenous
and endogenous antigen.
dinarily, they are important for the turnover of used or defective cellular proteins.
But, in the infected cell, they may provide an important immunological signal of
viral infection in the form of antigenic peptides on the cell surface in association
with MHC antigens. Further progress may depend on finding selective inhibitors
ofthe nonendosomal pathway, so that itsunique physiological role canbe determined.
Our results on the processing of HBsAg for T cell stimulation are summarized
in Fig. 3. Exogenous antigenis endocytosed by the APC and partially degraded into
antigenic fragments. Endogenously expressed antigen is processed in asimilarmanner.
The processed peptides associate with MHC antigens on the surface of the APC.
Receptor bindingtriggers theTcell response, includingproliferation and IL-2 produc-
tion. It does not matter to the T cell whether the antigen comes into the culture
as anative protein or apeptide, since only peptides are able to associate with MHC
and stimulate T cells. The model shows two possible processing pathways: one is
endosomal and wouldbe inhibited by leupeptinor chloroquine; the otheris nonen-
dosomal and insensitive to these inhibitors. As reported by others (5, 15, 37), in-
dividual T cellsseethe products of onepathway or the other, but notboth. However,
in contrast to those reports, we find that exogenous antigen is not limited to the en-
dosomal pathway, but also can be processed via the nonendosomal pathway (Table
V). Inhibition ofthe endosomalpathway has no effect on nonendosomal processing
ofexogenousantigen, suggesting that the twopathways are independent andoperate
in parallel with each other. Secondly, we find that endogenous antigen is not limited
to thenonendosomal pathway, but can also be processed via the endosomal pathway
(Tables V and VI). Peptides produced from endogenous proteins show the same
antigenicity (Table III and Fig. 2) and the same sensitivity to endosomal inhibitors
as do peptides produced from exogenous proteins.
In light ofthe fact that all ofour exogenous HBsAg-specific T cells crossreact with
endogenous antigen, we have tried to understand why none ofthe influenza nucleo-
protein andhemagglutinin-specific clones do so (5, 15). There are two majordiffer-
ences between the types ofT cell clones studied. Ours were proliferative clones fromJIN ET AL.
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noninfecteddonors who received acomponentvaccine. Theirs were cytolytic clones
from mice that were acutelyinfected with live virus. Thedifference between prolifer-
ative and cytolytic T cells seemsunlikely to explainadifference in antigen processing,
sincethe TCRis substantially the same forboth types ofclones (38, 39) so the recog-
nition of peptide-MHC complexes should be similar.
Alternatively, different T cell clones may be elicited by live virusthan by vaccina-
tion with purified viral components. Fortunately, thevaccine-immune T cells cross-
reactwith both endogenous andexogenousantigens, even though theinfection-derived
T cells apparently do not.
Each of our three clones (plus two others not shown) was able to recognize en-
dogenously expressedHBsAgas well as exogenousantigen. This is in spite ofimmu-
nization in vivo with noninfectious vaccine antigen and propagation of the T cell
lines in vitro with exogenous antigen. Further, we have tested whether recognition
of endogenous HBsAg could be explained as secretion by infected cells followed by
reuptake and presentation of exogenous antigen by uninfected APCs. No evidence
for this mechanismwas detected in the mixing experiment (Table IV). In addition,
endogenous pre,S + S antigen expressed by v73 is not secreted but remains cell
associated where it is recognized by the T cells. Recognition of endogenous antigen
by T cells immune to exogenous HBsAg was a general finding with every one of
ourT cell linesandapplied to both MHC class I- and classII-specific Tcells. Thus,
a noninfectious viral component vaccine can elicit active T cell immunity against
infection with live virus.
Summary
We have studiedthe antigen specificity and processingrequirements ofthreevaccine-
inducedcloned humanTcell lines specific forHBsAg, the envelope protein ofhepa-
titis B virus. Each T cell line recognized endogenously expressed antigen as well
as exogenous antigen. Two clones required endosomal processing, both for exoge-
nous andendogenous antigen; whilethe other Tcell line depended on nonendosomal
processing to generate antigenic peptides from both endogenous and exogenous an-
tigen. Thus, the two processing pathways are accessible to exogenous and endoge-
nous antigen. These results suggest that vaccine-induced T cells can participate ac-
tively in the immune response to live virus.
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